Abstract
Background Yellow fever (YF) is a viral haemorrhagic fever endemic in tropical regions of Africa and South America. Current intervention policies, namely the Eliminate Yellow fever Epidemics (EYE) strategy are actioned through vaccination. However, the stockpiles and production mean that vaccination can be in short supply. As such, intervention strategies need to be optimised; one of the tools for doing this is mathematical modelling.
Methods We fit a generalised linear model of YF reports to occurrence data available from 1987 to 2019 in Africa and South America and available serology survey data to estimate the force of infection across the continents. Then, using demographic and vaccination data, we examine the impact of interventions.
Findings We estimate that in 2018 there were approximately 51,000 (95%CrI [31,000 - 82,000]) deaths due to YF in Africa and South America. When we examine the impact of mass vaccination campaigns in Africa, these amount to approximately 10,000 (95%CrI [6,000 - 17,000]) deaths averted in 2018 due to mass vaccination activities in Africa; this corresponds to a 47% reduction (95%CrI [10% - 77%]).
Interpretation We find that the majority, 92% (95%CrI [89% - 95%]), of global burden occurs in Africa and that mass vaccination activities have significantly reduced the current deaths per year due to YF. This methodology allows us to evaluate the effectiveness of vaccination campaigns past, present and future and illustrates the need for continued vigilance and surveillance of YF.
Funding BMGF and MRC
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
KAMG & TG acknowledge funding from BMGF (OPP1117543, OPP1157270). KAMG, ATPH, TG, NMF acknowledge funding from MRC (MR/R015600/1). This work was carried out as part of the Vaccine Impact Modelling Consortium, which is funded by Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation. The views expressed are those of the authors and not necessarily those of the Consortium or its funders. The final decision on the content of the publication was taken by the authors.We acknowledge joint Centre funding from the UK Medical Research Council and Department for International Development. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
using secondary data only
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Public repository data: Vaccination coverage: coverage is available to download from the PoLiCi shiny app: https://shiny.dide.imperial.ac.uk/polici/. Serology surveys: There are seven published surveys used, available at DOI:10.1016/0147-9571(90)90521-T, DOI:10.1093/trstmh/tru086, DOI: 10.1186/s12889-018-5726-9, DOI: 10.4269/ajtmh.2006.74.1078, PMID: 3501739, PMID: 4004378, PMID: 3731366 Demographic data: Population level data was obtained from UN WPP https://population.un.org/wpp/, this was disaggregated using Landscan 2014 data https://landscan.ornl.gov/landscan-data-availability. Environmental data: This was obtained from LP DAAC: https://lpdaac.usgs.gov/ and worldclim http://www.worldclim.org/ Yellow fever outbreaks: These were compiled from the WHO weekly epidemiologic record and disease outbreak news https://www.who.int/wer/en/ and https://www.who.int/csr/don/en/. Data elsewhere: The data from the WHO YF surveillance database and from recent serological surveys from WHO member states in Africa underlying the results presented in the study are available from World Health Organization (contact: William Perea, pereaw{at}who.int or Laurence Cibrelus, cibrelusl{at}who.int or Jennifer Horton, jhorton{at}who.int). Data from the occurrence of YF in Brazil were obtained from the Brazilian MoH (contact: Daniel Garkauskas Ramos).
